感染症診断市場：製品、技術、検査タイプ、サンプル、用途、エンドユーザー別-2025-2030年世界予測

感染症診断市場は、2023年に247億6,000万米ドルと評価され、2024年には264億4,000万米ドルに達すると予測され、CAGR 7.29%で成長し、2030年には405億3,000万米ドルに達すると予測されています。

感染症診断市場には、病原体やその原因となる病気を迅速かつ正確に特定するための技術やテクノロジーが含まれています。この分野は、感染症という世界の課題が進行しており、効果的な治療と管理対策を促進するためのタイムリーな診断の必要性が強調されているため、極めて重要です。診断薬は、臨床検査室や病院から、家庭でのポイントオブケア検査や地域保健プログラムに至るまで、様々な場面で応用され、公衆衛生の成果や患者の管理戦略に影響を及ぼしています。エンドユーザーはヘルスケアプロバイダー、製薬会社、研究機関、政府機関など多岐にわたる。この市場の成長は、感染症の発生率の増加、分子診断技術の進歩、病気の早期発見の必要性に対する意識の高まり、研究イニシアティブに対する政府からの資金援助などの要因によって推進されています。COVID-19のパンデミックは緊急の需要にスポットライトを当て、複数の病原体を同時に検査できるマルチプレックス診断技術の急増につながり、次世代シーケンシングやAI駆動型診断ツールのような分野への投資機会を開いています。しかし、市場拡大は、検査機器や試薬の高コスト、厳しい規制状況、低資源環境における診断技術へのアクセスと適用における課題などのハードルに直面しています。戦略的な提言としては、未サービス市場に対応するため、携帯可能でコスト効率の高い診断検査のイノベーションに注力すること、より正確で追跡可能な電子カルテと診断を統合するデジタル・プラットフォームの開発に投資することが挙げられます。研究開発はまた、感度と特異度を向上させるために既存の技術を改良し、診断能力を拡大することも検討すべきです。持続可能な成長を確保するためには、技術力とアクセシビリティの両方を強化するために、政府、民間セクター、学界の協力的パートナーシップが推奨されます。市場はダイナミックであり、急速な技術進歩や、世界的に勃興・再興しつつある感染症に対する効率的でスケーラブルなソリューションに対する差し迫ったニーズが特徴です。

市場力学：急速に進化する感染症診断市場の主要市場インサイトを公開

感染症診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の感染症の流行と定期的なアウトブレイクの増加
  • 集中型検査室から分散型ポイントオブケア検査へのシフト
  • 感染症対策と予防に向けた政府の積極的な取り組みと投資
• 市場抑制要因
  • 新規診断技術の使用を制限する不十分な償還とヘルスケアコストの上昇
• 市場機会
  • 感染症診断キットおよびソリューションの進歩
  • 在宅ケア環境向けの感染症診断キットの登場
• 市場の課題
  • 精度の問題、熟練した専門家の不足

ポーターのファイブフォース感染症診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：感染症診断市場における外部からの影響の把握

外部マクロ環境要因は、感染症診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析感染症診断市場における競合情勢の把握

感染症診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス感染症診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、感染症診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨感染症診断市場における成功への道筋を描く

感染症診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の世界の蔓延と定期的な発生の増加
    • 集中型の検査室から分散型の臨床検査室への重点の移行
    • 感染症の制御と予防に向けた政府の支援的な取り組みと投資
  • 抑制要因
    • 不十分な償還とヘルスケア費の上昇により、新しい診断技術の使用が制限されている
  • 機会
    • 感染症診断キットとソリューションの進歩
    • 在宅医療現場向け感染症診断キットの登場
  • 課題
    • 精度の問題と熟練した専門家の不足
• 市場セグメンテーション分析
  • 製品：感染症診断のための分析機器の応用の進歩
  • テストの種類：利便性と緊急時のアプリケーションのためのPoint-of-Care（PoC）テストの導入が増加
  • 用途：ウイルス感染の診断に病気診断キットの利用が増加
  • エンドユーザー：病院における感染症診断製品の普及
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 感染症診断市場：製品別

• 機器
• 試薬
• ソフトウェアとサービス

第7章 感染症診断市場：技術別

• 生化学技術
• 従来の技術
• 分子技術

第8章 感染症診断市場テストの種類別

• 臨床検査
• PoCテスト

第9章 感染症診断市場サンプル

• 血液、血漿、血清
• 尿

第10章 感染症診断市場：用途別

• 細菌感染
• 心血管感染症
• 中枢神経系感染症
• 真菌感染症
• 性感染症
• ウイルス感染

第11章 感染症診断市場：エンドユーザー別

• 診断検査室
• 病院
• 調査機関

第12章 南北アメリカの感染症診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の感染症診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの感染症診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Medix Biochemica、感染症抗体の提供拡大のため米国ViroStatを買収
  • オックスフォード・ナノポアとビオメリュー、革新的な感染症診断法の開発に向けて戦略的提携契約を締結
  • サーモフィッシャーサイエンティフィック、インドで感染症検出用PCRキットを発売
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Adaptive Biotechnologies Corporation
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Techne Corporation
• bioMerieux SA
• Cardinal Health Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Grifols, S.A.
• Hologic Inc.
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• Konica Minolta, Inc.
• Labsystems Diagnostics Oy
• Merck KGaA
• Olympus Corporation
• Perkin Elmer, Inc.
• Pfizer Inc.
• Qiagen N.V.
• Quest Diagnostics
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. INFECTIOUS DISEASE DIAGNOSTIC MARKET RESEARCH PROCESS
• FIGURE 2. INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFECTIOUS DISEASE DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFECTIOUS DISEASE DIAGNOSTIC MARKET DYNAMICS
• TABLE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BIOCHEMICAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MOLECULAR TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, PLASMA, & SERUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CARDIOVASCULAR INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CNS INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 55. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 87. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 92. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 93. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 193. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 194. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 195. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 196. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 216. POLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. POLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 218. POLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 219. POLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 220. POLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. POLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. QATAR INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. QATAR INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 224. QATAR INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 225. QATAR INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 226. QATAR INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 227. QATAR INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 282. INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 283. INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

The Infectious Disease Diagnostic Market was valued at USD 24.76 billion in 2023, expected to reach USD 26.44 billion in 2024, and is projected to grow at a CAGR of 7.29%, to USD 40.53 billion by 2030.

The infectious disease diagnostic market encompasses techniques and technologies used to identify pathogens and the diseases they cause rapidly and accurately. This sector is vital due to the ongoing global challenge of infectious diseases, emphasizing the need for timely diagnosis to facilitate effective treatment and control measures. Diagnostics are applied in various settings, from clinical labs and hospitals to point-of-care testing at home and community health programs, influencing public health outcomes and patient management strategies. End-users range across healthcare providers, pharmaceutical companies, research institutes, and governmental bodies. Growth in this market is propelled by factors such as the increasing incidence of infectious diseases, advancements in molecular diagnostics technologies, heightened awareness about the need for early disease detection, and government funding for research initiatives. The COVID-19 pandemic has spotlighted urgent demands, leading to a surge in multiplex diagnostic technologies that can concurrently test for multiple pathogens, opening opportunities for investment in areas like next-generation sequencing and AI-driven diagnostic tools. However, market expansion faces hurdles such as high costs of testing equipment and reagents, strict regulatory landscapes, and challenges in accessing and applying diagnostic technologies in low-resource settings. Strategic recommendations include focusing on innovations in portable and cost-effective diagnostic tests to serve unserved markets and investing in the development of digital platforms that integrate diagnosis with electronic medical records for better accuracy and tracking. Research and development should also consider refining existing technologies to improve sensitivity and specificity, thereby broadening diagnostic capabilities. To ensure sustainable growth, collaborative partnerships between governments, private sectors, and academia are recommended to enhance both technological capabilities and accessibility. The market is dynamic, characterized by rapid technological advancements and a pressing need for efficient, scalable solutions to globally emerging and re-emerging infectious diseases.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Disease Diagnostic Market

The Infectious Disease Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing global prevalence and periodic outbreaks of infectious diseases
  • Shift in focus towards decentralized point-of-care testing from centralized laboratories
  • Supportive government initiatives and investments toward infectious disease control and prevention
• Market Restraints
  • Inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques
• Market Opportunities
  • Advancements in infectious disease diagnostics kits and solutions
  • Emergence of infectious disease diagnostics kits for homecare settings
• Market Challenges
  • Accuracy issues and limited availability of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Disease Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Disease Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Disease Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Disease Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Disease Diagnostic Market

A detailed market share analysis in the Infectious Disease Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Disease Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Disease Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Disease Diagnostic Market

A strategic analysis of the Infectious Disease Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Techne Corporation, bioMerieux SA, Cardinal Health Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Grifols, S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Labsystems Diagnostics Oy, Merck KGaA, Olympus Corporation, Perkin Elmer, Inc., Pfizer Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments, Reagents, and Software & Services.
• Based on Technology, market is studied across Biochemical Technology, Conventional Technology, and Molecular Technology.
• Based on Testing Type, market is studied across Laboratory Testing and PoC Testing.
• Based on Sample, market is studied across Blood, Plasma, & Serum and Urine.
• Based on Application, market is studied across Bacterial Infection, Cardiovascular Infection, CNS Infection, Fungal Infection, Sexually Transmitted Disease, and Viral Infection.
• Based on End User, market is studied across Diagnostic Laboratories, Hospital, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing global prevalence and periodic outbreaks of infectious diseases
    • 5.1.1.2. Shift in focus towards decentralized point-of-care testing from centralized laboratories
    • 5.1.1.3. Supportive government initiatives and investments toward infectious disease control and prevention
  • 5.1.2. Restraints
    • 5.1.2.1. Inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in infectious disease diagnostics kits and solutions
    • 5.1.3.2. Emergence of infectious disease diagnostics kits for homecare settings
  • 5.1.4. Challenges
    • 5.1.4.1. Accuracy issues and limited availability of skilled professionals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Advancing applications of analytical instruments for infectious disease diagnostics
  • 5.2.2. Testing Type: Emerging adoption of Point-of-Care (PoC) testing for convenience and emergency applications
  • 5.2.3. Application: Increasing use of disease diagnosis kits to diagnose viral infections
  • 5.2.4. End-User: Penetration of infectious disease diagnosis products in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Infectious Disease Diagnostic Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents
• 6.4. Software & Services

7. Infectious Disease Diagnostic Market, by Technology

• 7.1. Introduction
• 7.2. Biochemical Technology
• 7.3. Conventional Technology
• 7.4. Molecular Technology

8. Infectious Disease Diagnostic Market, by Testing Type

• 8.1. Introduction
• 8.2. Laboratory Testing
• 8.3. PoC Testing

9. Infectious Disease Diagnostic Market, by Sample

• 9.1. Introduction
• 9.2. Blood, Plasma, & Serum
• 9.3. Urine

10. Infectious Disease Diagnostic Market, by Application

• 10.1. Introduction
• 10.2. Bacterial Infection
• 10.3. Cardiovascular Infection
• 10.4. CNS Infection
• 10.5. Fungal Infection
• 10.6. Sexually Transmitted Disease
• 10.7. Viral Infection

11. Infectious Disease Diagnostic Market, by End User

• 11.1. Introduction
• 11.2. Diagnostic Laboratories
• 11.3. Hospital
• 11.4. Research Institutes

12. Americas Infectious Disease Diagnostic Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Infectious Disease Diagnostic Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Infectious Disease Diagnostic Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering
  • 15.3.2. Oxford Nanopore and bioMerieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
  • 15.3.3. Thermo Fisher Scientific Launches PCR Kits for Infectious Disease Detection in India
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adaptive Biotechnologies Corporation
• 3. Agilent Technologies, Inc.
• 4. Becton, Dickinson and Company
• 5. Bio-Techne Corporation
• 6. bioMerieux SA
• 7. Cardinal Health Inc.
• 8. Danaher Corporation
• 9. F. Hoffmann-La Roche Ltd.
• 10. GE Healthcare
• 11. Grifols, S.A.
• 12. Hologic Inc.
• 13. Illumina, Inc.
• 14. Johnson & Johnson Services, Inc.
• 15. Konica Minolta, Inc.
• 16. Labsystems Diagnostics Oy
• 17. Merck KGaA
• 18. Olympus Corporation
• 19. Perkin Elmer, Inc.
• 20. Pfizer Inc.
• 21. Qiagen N.V.
• 22. Quest Diagnostics
• 23. Siemens Healthineers AG
• 24. Sysmex Corporation
• 25. Thermo Fisher Scientific, Inc.